Septerna, Inc. announced positive progress in its drug pipeline with successful Phase 1 results for SEP-631 and the start of a Phase 1 trial for SEP-479, targeting chronic spontaneous urticaria and hypoparathyroidism respectively. The company reported a net loss of $8.6 million in Q1 2026 but holds a strong cash position of $522.1 million, expected to support operations into 2029. Upcoming milestones include a Phase 2b trial for SEP-631 in the second half of 2026 and data from SEP-479's trial expected by late 2026 or early 2027. Septerna continues to develop therapies for multiple diseases using its proprietary Native Complex Platform® and maintains collaborations with Novo Nordisk.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
